WASHINGTON (Legal Newsline) — The Federal Trade Commission
(FTC) has approved a modified final order that settles anti-competitive allegations for
Hikma Pharmaceuticals PLCS’s $2 billion acquisition of Roxane Laboratories Inc.
and Boehringer Ingelheim Roxane Inc.
To complete the acquisition under terms of the order, Hikma
must divest the rights and assets for two generic drugs, prednisone tablets and
lithium carbonate capsules, to Pennsylvania-based Renaissance Pharma Inc.
Additionally, Hikma is required to relinquish the rights to
market flecainide acetate tablets in the United States to India-based Unimark
Remedies Ltd., its drug development partner. Hikma will also divest equity
interest in Unimark, the FTC said.
The FTC voted 3-0 to approve the modified final order.